![Benjamin John Nathan Griffiths](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Historial de carrera de Benjamin John Nathan Griffiths
Antiguos cargos conocidos de Benjamin John Nathan Griffiths.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
Abcellute Ltd.
![]() Abcellute Ltd. Miscellaneous Commercial ServicesCommercial Services Abcellute was founded in September 2001 as a spinout from the school of biosciences, Cardiff University. Abcellute's core technology is proprietary media Sure Tran -that enables the extended use of fresh cells with out the need for cryopreservation. The company's vision is to achieve global adoption of its SureTran cell transport technology by providing the research community with enhanced, fresh-cell systems. These will maximize the utilization of this often scarce resource and provide products that are much more convenient to use than current fresh-cell systems. This will deliver benefits to biomedical researchers in key areas such as pre-clinical drug evaluation and regenerative medicine. | Director Técnico/Científico/I+D | 01/09/2001 | 20/11/2012 |
Fundador | 19/04/2010 | 20/11/2012 |
Estadísticas
Internacional
Reino Unido | 2 |
Operativa
Chief Tech/Sci/R&D Officer | 1 |
Founder | 1 |
Sectorial
Commercial Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas privadas | 1 |
---|---|
Abcellute Ltd.
![]() Abcellute Ltd. Miscellaneous Commercial ServicesCommercial Services Abcellute was founded in September 2001 as a spinout from the school of biosciences, Cardiff University. Abcellute's core technology is proprietary media Sure Tran -that enables the extended use of fresh cells with out the need for cryopreservation. The company's vision is to achieve global adoption of its SureTran cell transport technology by providing the research community with enhanced, fresh-cell systems. These will maximize the utilization of this often scarce resource and provide products that are much more convenient to use than current fresh-cell systems. This will deliver benefits to biomedical researchers in key areas such as pre-clinical drug evaluation and regenerative medicine. | Commercial Services |